colorectal cancer
Conditions
Interventions
Treatment group and control group: strengthening spleen and relieving toxin decoction combination with first-line chemotherapy
Sponsors
ShuGuang Hospital Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: All patients who were included in the trial were to meet all of the following conditions: 1. Clear cytology or pathology diagnosis of mCRC, the operation or imaging examination stage for the IV period; 2. The bank has been the first-line chemotherapy treatment and access to CR, PR, SD with the expected survival time more than 6 months of the initial treatment of patients; 3. There are at least 1 imaging examinations (PET-CT, CT, MRI, bone scan, X-ray) showed measurable lesions; 4. With the spleen deficiency and dampness heat syndrome diagnosis; 5. The men and women, aged 18-75 years old. Body condition score ECOG (0 ~ 1) or KPS = 70; 6. The peripheral blood of normal liver and kidney function, no obvious abnormal ECG is normal. Indications for maintenance chemotherapy; 7. The patients with good compliance, can understand the research situation and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Does not conform to the diagnosis and inclusion criteria, the diagnosis of unknown; 2. There are serious diseases of the cardiovascular system, urinary system diseases, blood system diseases, digestive system diseases, and can not withstand the test; 3. A mental disorder, which is difficult to control during pregnancy or lactation; 4. With the activities of tuberculosis and other serious infectious diseases; 5. We should not oral drugs or frequent vomiting; 6. The difference between the compliance; 7. To treat or use other drugs or other trial patients in a clinical trial can not be selected within the target in January.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;Disease remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| cytokine;cellular immunity; | — |
Countries
China
Contacts
Public ContactFu Xiaoling
Outcome results
None listed